Predictive Oncology Inc. POAI Archives - Page 12 of 19

FridayMay 29, 2020 1:10 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory

Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://ibn.fm/8knZX). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring…

FridayMay 22, 2020 2:26 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Exchanges $2.1M Promissory Note for Common Stock

Predictive Oncology (NASDAQ: POAI) recently entered an agreement with POAI CEO Dr. Carl Schwartz to exchange a $2.1 million promissory note for newly issued equity (http://ibn.fm/lzYPh). An article discussing the company reads, “‘This agreement enables the company to strengthen its balance sheet and simplify its capital structure at a critical juncture in our quest to commercialize our highly valuable database of cancer tumors for the advancement of predictive medicine,’ Schwartz said in a news release. ‘At the same time, it reinforces my commitment and demonstrates my belief in our ability to emerge as a leader in the application of artificial…

FridayMay 22, 2020 12:05 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or…

ThursdayMay 14, 2020 11:14 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin*. Extremely versatile, the NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus.…

TuesdayMay 12, 2020 10:28 am

Predictive Oncology Inc. (NASDAQ: POAI) CEO Enters into Debt-to-Equity Agreement, Touts Company’s Major Asset

POAI CEO exchanges $2.1 million promissory note for newly issued stock shares Strategic agreement enables company to strengthen balance sheet, simplify capital structure in plan to commercialize highly valuable database Because of its unique patient inventory, Helomics is only company with ability to profile tumors In a significant move indicating strong confidence in the company’s future, Predictive Oncology Inc. (NASDAQ: POAI) CEO Dr. Carl Schwartz has entered into an agreement exchanging a $2.1 million promissory note for equity in the company, which has established itself as a leader in the cancer precision-medicine field. In addition, during a recent interview, Schwartz…

ThursdayMay 07, 2020 11:10 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces At-The-Market Priced $2.2M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock. According to the update, the shares are each $1.575, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $2.2 million. In addition, Predictive Oncology has agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. Subject to…

WednesdayMay 06, 2020 11:55 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According to the update, the groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein), which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things. NIH is currently exploiting the…

FridayMay 01, 2020 11:30 am

Predictive Oncology Inc. (NASDAQ: POAI) Streamlines Capital, Simplifies Balance Sheet through Debt Exchange

POAI CEO exchanges $2.1 promissory note for shares of common stock Agreement enables Predictive Oncology to strengthen balance sheet, simplify capital structure at critical juncture in quest to commercialize highly valuable database POAI cancels outstanding debt of $2,115,000 in aggregate principal amount of 12% promissory note Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, has entered into an agreement with its CEO to exchange a $2.1 million promissory note for newly issued equity (http://ibn.fm/lzYPh). The strategic move demonstrates the confidence CEO Dr. Carl Schwartz has in the growing company. “This agreement enables…

ThursdayApr 30, 2020 2:40 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing CancerQuest2020 Initiative

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently reported that its Helomics subsidiary is making headway toward its goal of developing an AI-driven predictive model of ovarian cancer (http://ibn.fm/mENY6). An article discussing the company reads, “This achievement will be a key milestone for the company’s CancerQuest2020 initiative. . . . CancerQuest2020 is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome leveraging Helomics’ huge knowledge base of tumor profiles. Predictive models embody the knowledge from these profiles to create a ‘computational…

ThursdayApr 23, 2020 9:21 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Agreement to Exchange $2.1M Debt for Equity

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Wednesday announced that it has entered into an exchange agreement with POAI chief executive officer Dr. Carl Schwartz regarding a $2.1 million promissory note of the company. Per the agreement, Dr. Schwartz has exchanged the note for 1,533,481 shares of newly issued common stock at an exchange rate of $1.43 each, the closing price of the common stock on April 21, 2020. Dr. Schwartz agreed to not sell or transfer 766,740 shares (one-half of the shares) for three months after…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI